苯达莫司汀

Description

Bendamustine · CAS 16506-27-7 · C16H21Cl2N3O2. UNII 9266D9P3PQ. LogP: 0.44.

Identification

CAS Registry Number	16506-27-7
PubChem CID	65628
Molecular formula	C16H21Cl2N3O2
IUPAC name	4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid
UNII (FDA)	9266D9P3PQ

Computed Descriptors

Molecular Weight	358.3
XLogP3	2.9
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	9
Exact Mass	357.1010823
Monoisotopic Mass	357.1010823
Topological Polar Surface Area	58.4
Heavy Atom Count	23
Formal Charge	0

Physical & Chemical Properties

LogP	0.44

Physical description & handling notes

• MW: 394.7 ... supplied as a sterile non-pyrogenic white to off-white powder. /Bandamustine hydrochloride/
• No mean changes in QTc interval greater than 20 milliseconds were detected up to one hour post-infusion.
• Parenteral: For injection, for IV infusion only: 100 mg Treanda (Cephalon). /Bendamustine hydrochloride/

GHS Hazard Classification

Reported hazard statements	H301 (100%), H341 (100%), H351 (100%), H360 (100%)

Documented Uses

• Alkylating drug indicated for the treatment of patients with chronic lymphocytic leukemia /Bandamustine hydrochloride/
• Bifunctional alkylating agent.[The Merck Index, Fourteenth Edition (2006)
• Therapeutic category: Antineoplastic
• Approved for B-cell non-Hodgkin lymphoma
• Bendamustine is indicated for use in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with [rituximab] or a rituximab-containing regimen. The indication for chronic lymphocytic leukemia (CLL) was removed from the US drug label in April 2024.
• Breast Feeding; Lactation; Antineoplastic Agents, Alkylating; Nitrosourea Compounds

Synonyms

Bendamustine; 16506-27-7; Bendamustina; 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid; Bendamustinum; DTXSID2046888; 9266D9P3PQ; 1H-Benzimidazole-2-butanoic acid, 5-(bis(2-chloroethyl)amino)-1-methyl-; DTXCID0026888; 5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric acid; 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}butanoic acid; omega-(1-Methyl-5-bis(beta-chloroethyl)aminobenzimidazole-(2)-butyric acid; 1H-benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-; 4-(5-(bis(2-chloroethyl)amino)-1-methylbenzimidazol-2-yl)butanoic acid; 4-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-1,3-benzodiazol-2-yl)butanoic acid; RefChem:54437

Frequently Asked Questions

What are the CAS number and molecular formula of Bendamustine?

CAS 16506-27-7; molecular formula C16H21Cl2N3O2; molecular weight — g/mol.

What other names is Bendamustine known by?

Bendamustine, 16506-27-7, Bendamustina, 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid, Bendamustinum, DTXSID2046888.

Is Bendamustine classified as hazardous?

Hazard statements reported: H301, H341, H351, H360.

What are the key physical properties of Bendamustine?

LogP: 0.44.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.